Advertisement

Antibacterial, Antifungal, and Antiviral Prophylaxis for Children Undergoing HSCT

Chapter
  • 111 Downloads

Abstract

Infections in pediatric patients who undergo HSCT can be caused by virus, bacteria, fungus, or protozoa. The most common infections in these patients include:

References

  1. 91.
    Hastings CA, Torkildson JC, Agrawal AK. Handbook of pediatric hematology and oncology: children’s Hospital & Research Center Oakland. 2nd ed. New York: Wiley Blackwell; 2013.Google Scholar
  2. 74.
    Licciardello M, Pegoraro A, Cesaro S. Prophylaxis and therapy of viral infections in pediatric patients treated for malignancy. Pediatr Rep. 2011;3(1):e5.CrossRefGoogle Scholar
  3. 81.
    Egan G, Robinson PD, Martinez JPD, et al. Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: a systematic review of randomized trials. Cancer Med. 2019;8(10):4536–46.CrossRefGoogle Scholar
  4. 52.
    Taketomo CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook. 21st ed. Hudson: Lexicomp; 2014.Google Scholar
  5. 82.
    Maertens J, Cesaro M, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplantation recipients. J Antimicrob Chemother. 2016;71(9):2397–404.CrossRefGoogle Scholar
  6. 73.
    Rowe RG, Guo D, Lee M, et al. Cytomegalovirus infection in pediatric hematopoietic stem cell transplantation: risk factors for primary infection and cases of recurrent and late infection at single center. Biol Blood Marrow Transplant. 2007;22(7):1275–83.  https://doi.org/10.1016/j.bbmt.2016.04.004.CrossRefGoogle Scholar
  7. 79.
    Science M, Robinson PD, McDonald T, et al. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014;61(3):393–400. http://www.c17.ca/files/5213/9343/4155/C17_Antifungal_Guideline_Feb_26_2014_Final_Full.pdf (Nov 21, 2019).CrossRefGoogle Scholar
  8. 80.
    Tran HL, Mahmoudjafari Z, Rockey M, et al. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease. J Oncol Pharm Pract. 2014;22(2):228–34.CrossRefGoogle Scholar
  9. 76.
    Yee-Guardino S, Gowans K, Yen-Lieberman B, et al. β-Herpesviruses in febrile children with cancer. Emerg Infect Dis. 2008;14(4):579.CrossRefGoogle Scholar
  10. 71.
    Lin A, Maloy M, Su Y, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience. Transpl Infect Dis. 2019;21(6):e13187.  https://doi.org/10.1111/tid.13187.CrossRefPubMedGoogle Scholar
  11. 72.
    Jain T, John J, Kotecha A, et al. Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab. Ann Hematol. 2015;95(8):1323–7.  https://doi.org/10.1007/s00277-016-2700-4.CrossRefGoogle Scholar
  12. 75.
    Kempf W, Meylan P, Gerber S, et al. Swiss recommendations for the management of varicella zoster virus infections. Swiss Med Wkly. 2007;137:239–51.PubMedGoogle Scholar
  13. 77.
    Fule JDR, Cheuk DK, Ha SY, Chiang AK, Chan GC. Human herpesvirus types 6 and 7 infection in pediatric hematopoietic stem cell transplant recipients. Ann Transplant. 2014;19:269–76.CrossRefGoogle Scholar
  14. 78.
    Moschovi M, Adamaki M, Vlahopoulos SA. Progess in treatment of viral infections in children with acute lymphoblastic leukemia. Oncol Rev. 2016;10(1):300. https://www.oncologyreviews.org/index.php/or/article/view/300/277#content/figure_reference_1 (Nov 20, 2019).CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.CuritibaBrazil

Personalised recommendations